Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
Proton pump inhibitor (PPI) is a prodrug which is activated by acid. Activated PPI binds covalently to the gastric H+, K+-ATPase via disulfide bond. Cys813 is the primary site responsible for the inhibition of acid pump enzyme, where PPIs bind. Omeprazole was the first PPI introduced in market, foll...
Main Authors: | Shin, Jai Moo, Kim, Nayoung |
---|---|
Format: | Online |
Language: | English |
Published: |
Korean Society of Neurogastroenterology and Motility
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548122/ |
Similar Items
-
Proton Pump Inhibitors in Pediatrics: Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics
by: Ward, Robert M., et al.
Published: (2013) -
Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor
by: Srivastava, Pratima
Published: (2012) -
Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update
by: Wedemeyer, Ralph-Steven, et al.
Published: (2014) -
Proton pump inhibitors and gastroenteritis
by: Hassing, Robert-Jan, et al.
Published: (2016) -
The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
by: Gu, Namyi, et al.
Published: (2016)